

Development 135, 3801–3811 (2008) doi:10.1242/dev.025825

# BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway

Nobuhiro Kamiya<sup>1</sup>, Ling Ye<sup>3</sup>, Tatsuya Kobayashi<sup>4</sup>, Yoshiyuki Mochida<sup>5</sup>, Mitsuo Yamauchi<sup>5</sup>, Henry M. Kronenberg<sup>4</sup>, Jian Q. Feng<sup>3</sup> and Yuji Mishina<sup>1,2,\*</sup>

Bone morphogenetic proteins (BMPs) are known to induce ectopic bone. However, it is largely unknown how BMP signaling in osteoblasts directly regulates endogenous bone. This study investigated the mechanism by which BMP signaling through the type IA receptor (BMPRIA) regulates endogenous bone mass using an inducible Cre-loxP system. When BMPRIA in osteoblasts was conditionally disrupted during embryonic bone development, bone mass surprisingly was increased with upregulation of canonical Wnt signaling. Although levels of bone formation markers were modestly reduced, levels of resorption markers representing osteoclastogenesis were severely reduced, resulting in a net increase in bone mass. The reduction of osteoclastogenesis was primarily caused by *Bmpr1a*-deficiency in osteoblasts, at least through the RANKL-OPG pathway. Sclerostin (*Sost*) expression was downregulated by about 90% and SOST protein was undetectable in osteoblasts and osteocytes, whereas the Wnt signaling was upregulated. Treatment of *Bmpr1a*-deficient calvariae with sclerostin repressed the Wnt signaling and restored normal bone morphology. By gain of Smad-dependent BMPRIA signaling in mice, *Sost* expression was upregulated and osteoclastogenesis was increased. Finally, the *Bmpr1a*-deficient bone phenotype was rescued by enhancing BMPRIA signaling, with restoration of osteoclastogenesis. These findings demonstrate that BMPRIA signaling in osteoblasts restrain endogenous bone mass directly by upregulating osteoclastogenesis through the RANKL-OPG pathway, or indirectly by downregulating canonical Wnt signaling through sclerostin, a Wnt inhibitor and a bone mass mediator.

**KEY WORDS:** BMP receptor IA, Bone mass, Canonical Wnt signaling, Osteoblast, Osteoclastogenesis, Sclerostin, Mouse

## INTRODUCTION

BMPs were discovered as potent inducers of ectopic bone formation when implanted subcutaneously (Urist, 1965). Studies of human disorders chondrodysplasia (Thomas et al., 1996) and fibrodysplasia ossificans progressiva (Shore et al., 2006) indicate the importance of BMP signaling in cartilage and muscle, respectively, suggesting that BMP signaling plays an important role in controlling mineralization in musculoskeletalogenesis. Bone is the primary component in skeletogenesis, and osteoblasts are the predominant cell type in bone. However, the mechanism by which BMP signaling in osteoblasts contributes the skeletogenesis has not been fully described.

The majority of bones, including long and ectopic bone, are formed through an endochondral process (Kronenberg, 2003). Condensed mesenchymal cells differentiate into chondrocytes to form a cartilage template that is later replaced by osteoblasts (Mackie et al., 2008; Maes et al., 2007). Mesenchymal cells and chondrocytes respond to BMP signaling to differentiate and maintain their features in vivo (Bandyopadhyay et al., 2006; Tsuji et al., 2006; Yoon et al., 2005). By contrast, during the alternate process of intramembranous bone formation, mesenchymal cells differentiate directly into osteoblasts without going through a cartilaginous phase. In this study, we genetically altered BMP

signaling in osteoblasts using a mouse model. To avoid secondary effects from chondrocytes on osteoblasts in the endochondral process, we primarily examined intramembranous bone formation (e.g. calvaria) and demonstrated the direct effects that BMP signaling has on osteoblasts.

BMP receptor type IA (BMPRIA), which is abundantly expressed in bone, is activated by major BMP ligands BMP2 and BMP4. Conventional knockout of BMP2, BMP4 and BMPRIA in mice leads to embryonic death before bone development (Mishina et al., 1995; Winnier et al., 1995; Zhang and Bradley, 1996). We previously disrupted *Bmpr1a* during adult stages in an osteoblast-specific manner using *Og2-Cre* mice (Mishina et al., 2004). This study suggests that the response of osteoblasts to loss of BMP signaling is age dependent, as bone volume decreased in young mice but increased in old mice. Similarly, the mechanism by which BMP signaling regulates bone mass is not straightforward, as loss-of-function of BMP2 and gain-of-function of BMP4 both reduce bone mass (Okamoto et al., 2006; Tsuji et al., 2006). Bone mass is determined by the balance of bone formation and resorption, and osteoblasts regulate both processes. Thus, we focused on osteoblasts and addressed the complicated effect of BMP signaling on bone mass.

Human genetic studies have shown that loss-of-function mutations in components of Wnt signaling, such as the Wnt coreceptor low-density lipoprotein receptor-related protein 5 (LRP5), is associated with osteoporosis (Gong et al., 2001; Patel and Karsenty, 2002). Dominant missense LRP5 mutations are associated with high bone mass (HBM) diseases (Boyden et al., 2002; Little et al., 2002; Van Wesenbeeck et al., 2003), indicating that canonical/ $\beta$ -catenin Wnt signaling enhances bone mass (Baron et al., 2006; Glass and Karsenty, 2006; Krishnan et al., 2006). In vitro, Wnt signaling induces BMP expression (Bain et al., 2003; Winkler et al., 2005), whereas BMPs induce Wnt expression (Chen et al., 2007; Rawadi

<sup>1</sup>Laboratory of Reproductive and Developmental Toxicology, NIEHS/NIH, Research Triangle Park, NC 27709, USA. <sup>2</sup>School of Dentistry, University Michigan, Ann Arbor, MI 48109, USA. <sup>3</sup>School of Dentistry, University of Missouri-Kansas City, Kansas City, MO 64108, USA. <sup>4</sup>Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. <sup>5</sup>Dental Research Center, University of North Carolina, Chapel Hill, NC 27599, USA.

\*Author for correspondence (e-mail: mishina@umich.edu)

et al., 2003), suggesting that both BMP and Wnt signaling may synergistically regulate each other in osteoblast, possibly through autocrine/paracrine loop. Both BMP and Wnt signaling induce bone mass; however, the mechanism by which BMP and Wnt signaling cooperate to affect bone mass is not well understood, particularly during embryonic development when bone mass dramatically increases.

Here, we have employed a tamoxifen-inducible Cre-loxP system under the control of a 3.2 kb type I collagen promoter and have disrupted or upregulated BMP signaling through BMPRI1A in osteoblasts during embryonic bone development. We unexpectedly found increased bone mass in response to loss of BMPRI1A in osteoblasts and a new interaction between BMP and Wnt signaling through sclerostin.

## MATERIALS AND METHODS

### Mice and tamoxifen administration

Mice expressing the tamoxifen (TM)-inducible Cre fusion protein Cre-ER<sup>TM</sup> (Danielian et al., 1998; Hayashi and McMahon, 2002) under the control of a 3.2 kb mouse pro-collagen *α1(I)* promoter (*Col1-CreER<sup>TM</sup>*), which is active in osteoblasts, odontoblasts and tendon fibroblasts (Rossert et al., 1995), were generated by pronuclear injection and crossed with floxed *Bmpr1a* mice (Mishina et al., 2002). Mice that conditionally express a constitutively active form of *Bmpr1a* (*caBmpr1a*), which has a mutation in the GS domain of BMPRI1A that results in ligand-independent activation of Smad signaling after Cre recombination, were generated using a transgenic construct similar to one previously reported (Fukuda et al., 2006) (see Fig. S4A in the supplementary material). *ROSA26* Cre reporter (*R26R*) (Soriano, 1999) and *TOPGAL* (DasGupta and Fuchs, 1999) mice were obtained from Dr Philippe Soriano and the Jackson Laboratory, respectively. Tamoxifen (TM; Sigma) was dissolved in a small volume of ethanol, diluted with corn oil at a concentration of 10 mg/ml. TM (75 mg/kg) was injected intraperitoneally daily into pregnant mice (100 to 200 ml/mouse) for at least 3 days starting at E13.5.

### Histological analysis and skeletal preparation

Whole-mount β-gal staining was performed as previously described (Mishina et al., 2004). For histological analysis, fetuses were fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned frontally for calvariae and sagittally for long bones at 6 μm. Sections were stained with Hematoxylin and Eosin or Eosin alone for β-gal stained samples. For von Kossa staining to detect mineral deposition, sections were covered with filtered 5% silver nitrate (Sigma), exposed to ultraviolet light for 45 minutes and placed in 5% sodium thiosulfate (Sigma) for a few seconds. For BrdU (bromodeoxyuridine) incorporation, 100 μM of BrdU (Roche) was injected into pregnant females intraperitoneally 2 hours before collecting calvariae. TRAP (tartrate resistant acid phosphatase) staining was performed using the leukocyte acid phosphatase kit (Sigma). Immunostaining was performed using primary antibodies against BMPRI1A (Orbigen) (Yoon et al., 2005) and phospho-Smad1, -Smad5, -Smad8 (Cell Signaling) and sclerostin (R&D). Alexa Fluor (488, 594, Molecular Probes) and ABC kit (Santa Cruz Biotechnology) were used for detection. Frozen frontal sections at 10 μm were prepared for phospho-Smad1, -Smad5 and -Smad8 antibodies. For skeletal preparations, mice were dissected and fixed in 100% ethanol, and then stained with Alcian Blue and Alizarin Red. To count total cell number in sections, 1 μM of DAPI was treated for 10 minutes.

### Quantitative real time RT-PCR (QRT-PCR)

RNA was isolated from calvariae using the Micro-FastTrack 2.0 Kit (Invitrogen). cDNA was synthesized using the SuperScript Preamplification System (GIBCO). PCR reactions, data quantification and analysis were performed (Applied Biosystems). Values were normalized to *Gapdh* using the 2<sup>-ΔΔCt</sup> method (Livak and Schmittgen, 2001).

### Calvaria and osteoblast culture

For ex vivo bone culture, newborn calvariae were dissected at the sagittal suture and cultured in modified BGJ (Invitrogen) supplemented with ascorbic acid (Sigma, 50 mg/ml) and 5% fetal bovine serum for the first

24 hours in culture. Hemicalvariae were treated with 4-hydroxyl TM (Sigma, 100 ng/ml) and sclerostin (R&D, 50 ng/ml) in the absence of serum for 5 days. For in vitro culture, osteoblasts were isolated from conditional knockout (cKO) and wild-type newborn calvariae, and cultured in the same media with addition of 4-hydroxyl TM (Sigma, 100 ng/ml) every other day.

## RESULTS


### Tissue specificity and efficiency of Cre recombinase in *Col1-CreER<sup>TM</sup>* mice

Tamoxifen (TM)-inducible *Col1-CreER<sup>TM</sup>* mice were mated to *ROSA26* reporter mice (*R26R*) to monitor Cre activity assessed by staining for β-galactosidase (β-gal). When TM was injected at embryonic day (E) 13.5 or earlier (E10.5), β-gal positive cells were first visible at E14.5 both in intramembranous and endochondral bones (data not shown). Daily injections for 3 days from E13.5 established strong β-gal activity at E18.5 (Fig. 1A). Neither Cre negative littermates nor Cre-positive embryos that did not receive TM showed β-gal activity (Fig. 1A, data not shown). Cre is active in immature periosteum wrapping growth plates, in osteogenic centers and in bone collars, but not in chondrocytes (Fig. 1B). By β-gal staining of whole calvariae, the positive areas started at the temporal border of parietal bones and expanded gradually as intramembranous bone formation progressed from E15.5 to E18.5 (Fig. 1C), where Cre was active in osteoblasts by histology. These results demonstrate the specificity and efficiency of Cre recombinase in *Col1-CreER<sup>TM</sup>* mice during embryonic bone development.

### Developmental abnormalities in BMPRI1A cKO bones

*Col1-CreER<sup>TM</sup>* mice were bred into mice homozygous for floxed *Bmpr1a*. *Bmpr1a* cKO fetuses (cKO, *Cre+*; *Bmpr1a* *fx/fx*) and wild-type controls (WT, *Cre-*; *Bmpr1a* *fx/fx*) were collected after daily TM injection into pregnant female from E13.5. Gross morphology of E18.5 cKO was normal (data not shown). Production of BMPRI1A was suppressed in osteoblasts and osteocytes in the cKO (Fig. 1D), demonstrating efficient and specific loss-of-function of BMPRI1A in cKO osteoblasts. Phosphorylated Smad 1/5/8 was modestly reduced in cKO (Fig. 1E), presumably owing to remaining signals from other type I receptors, such as BMPRI1B and ACVR1.

Mineralization was increased in cKO parietal bones when assessed by Alizarin Red staining, although skeletal shape in the forelimb and hindlimb were unchanged (Fig. 2A). The ratio of bone volume to total tissue volume (BV/TV) was 30% higher in cKO calvariae and femora at E18.5 when assessed by micro computed tomography (μCT) (Fig. 2B). Hematoxylin and Eosin staining of E18.5 calvariae demonstrated that cKO parietal bones were markedly thicker than wild type (Fig. 2C). The cKO bony area positive for Eosin was loose, discontinuous and disorganized, whereas in wild type it was compact and lamellar in structure. Von Kossa staining for Ca<sup>2+</sup> in mineralized tissue showed increases in mineralized area of cKO calvariae where bone continuity was disrupted (Fig. 2D). In cKO femora where bone mass was increased (Fig. 2B), woven bone was increased in the primary spongiosa (Fig. 2E). By BrdU incorporation for detection of proliferating cells in vivo, positive cells per total cells in bone were unchanged in cKO calvaria (Fig. 2F). These facts suggest that bone mass of cKO was increased both in calvariae and femora, which follow intramembranous and endochondral ossification, respectively.



**Fig. 1. Tamoxifen (TM)-dependent and osteoblast-specific Cre activity using Cre-ER<sup>TM</sup> mice.** (A) Cre-ER<sup>TM</sup> transgenic mice mated with ROSA26 Cre reporter mice (R26R). TM was injected daily into pregnant females for 3 days from E13.5 to E15.5. Cre-negative and -positive littermates were stained for β-gal at E18.5. (B) Cre activity in long bones. Forelimbs were stained for β-gal at E18.5. C, chondrocytes; black arrow, periosteum; red arrow, osteogenic center. Scale bars: 50 μm. (C) Cre recombination in calvariae at E15.5, E16.5 and E18.5 in whole head (lateral and overhead views) and histology of E18.5 calvariae. Broken line, areas of parietal bones (P). Scale bar: 20 μm. (D) BMPR1A as evaluated by immunohistochemistry using cKO calvariae at E18.5. BMPR1A, green; DAPI (nuclei), blue. Scale bars: 10 μm. (E) Immunoblotting for phosphorylated Smad 1/5/8 using E18.5 calvariae. The membrane was treated with polyclonal rabbit anti-phospho-Smad1/5/8 (1:1000) and monoclonal mouse anti-beta-actin (1:2000), and visualized by ECL.

### Effects of BMPR1A signaling on bone formation and resorption markers


Bone mass is determined by the balance between bone formation and resorption. We examined changes in bone formation markers using calvariae and QRT-PCR. Expression of *Runx2* and osterix (*Sp7*), genes that are required for osteoblast differentiation, and bone sialoprotein (*Ibsp*), which is induced rapidly prior to calcification, were reduced in E16.5 cKO (Fig. 3A). However, expression of these genes, as well as of alkaline phosphatase (*Akp2*; *Alpl* – Mouse Genome Informatics) and osteocalcin (*Bglap2*) was unchanged at E18.5. In addition, alkaline phosphatase activity was also unchanged at E18.5 (data not shown). These results suggest that bone formation is modestly reduced in E16.5 cKO calvariae, which could impact the phenotype of E18.5.

Among bone resorption markers expressed by osteoclasts, expressions of *Mmp9* and cathepsin K (*Ctsk*) were decreased 25% and 35% in E19.5 cKO calvariae, respectively, and that of tartrate resistant acid phosphatase (*Trap*) was reduced 30% and 35% at E18.5 and E19.5, respectively (Fig. 3B). Osteoclastogenesis is regulated by RANKL (receptor activator of NFκB ligand), an osteoclast differentiation factor, and OPG (osteoprotegerin), a decoy receptor for RANKL, both expressed by osteoblasts (Simonet et al., 1997). *Rankl* expression was reduced 30% at E19.5, and *Opg* was increased 50% and 80% at E18.5 and E19.5, respectively (Fig. 3B), resulting in the reduction of the ratio, *Rankl* to *Opg*, by 30% and 60% at E18.5 and E19.5, respectively (Fig. 3C). As RANKL

stimulates osteoclastogenesis, whereas OPG inhibits it, these changes were consistent with the reduced osteoclastogenesis in cKO calvariae (Fig. 3B). Consistent with these data, osteoclast activity evaluated by TRAP staining was significantly reduced in cKO calvariae at E18.5 (Fig. 3D). In addition, expressions of other BMP receptors type I (*Bmpr1b*, *Acvr1*), type II (*Bmpr2*, *Acvr2a*, *Acvr2b*) and their ligands (*Bmp2*, *Bmp4*, *Bmp6* and *Bmp7*), were not increased in cKO calvariae at E18.5 when assessed using QRT-PCR (Fig. 3E), suggesting that a compensation for the loss of BMPR1A by other BMP receptors or ligands is unlikely. These results suggest that osteoclastogenesis in cKO calvariae was decreased by loss of BMPR1A.

### Effects of BMPR1A signaling on OPG and RANKL in vitro

*Bmpr1a*-deficient osteoblasts were reproduced by infecting primary osteoblasts from *Bmpr1a* *fx/fx* calvariae with recombinant adenovirus expressing Cre protein. Expressions of *Bmpr1a* and *Rankl* were reduced 70% and 40%, respectively, whereas *Opg* increased 2.5-fold in cKO osteoblasts (CRE) compared with control (Mock) (see Fig. S1A in the supplementary material), resulting in reduced ratio of *Rankl* to *Opg* by 80% (see Fig. S1A in the supplementary material). These indicate reduced osteoclastogenesis in *Bmpr1a*-deficient osteoblasts at least through the RANKL-OPG pathway, consistent with in vivo data (Fig. 3).



**Fig. 2. Increased bone mass in *Bmpr1a* cKO mice.** (A) Skeletal preparation of the skull and long bones at E18.5 using Alizarin Red/Alcian Blue staining. Broken line, areas of parietal bones (P). (B) Bone volume over total tissue volume (BV/TV) obtained from  $\mu$ CT analysis on parietal bones of the skull (left) and femur (right) at E18.5. Values are expressed as mean $\pm$ s.d. (wild type,  $n=5$ ; cKO,  $n=4$ , Student's  $t$ -test; \* $P<0.01$ ). (C) Hematoxylin and Eosin staining of E18.5 calvariae. Boxed areas in frontal sections were magnified. Scale bars: 25  $\mu$ m. (D) Von Kossa staining for  $Ca^{2+}$  using E18.5 calvariae. Scale bars: 25  $\mu$ m. (E) Hematoxylin and Eosin staining of E18.5 humerus. Boxed areas in sagittal sections are magnified. Scale bars: 100  $\mu$ m. (F) BrdU incorporation using E18.5 calvariae. BrdU-positive cells (arrows) per total cells in bone were unchanged. Scale bars: 25  $\mu$ m.

Monocytic cells, precursors of osteoclasts, were isolated from adult cKO and wild-type spleens, and were induced by RANKL and M-CSF. There was no difference both in osteoclast number and *Bmpr1a* expression levels between wild-type and cKO cells (see Fig. S1B,C in the supplementary material), suggesting that cKO osteoclasts are intact and able to fully accomplish osteoclastogenesis by responding to these cytokines. Next, a mixture of osteoblasts and osteoclasts was isolated from adult cKO and wild-type bone marrow cells independently, and induced by  $1\alpha, 25$ -dihydroxyvitamin  $D_3$ . The cKO mixture was defective in osteoclast number and *Bmpr1a* expression levels (see Fig. S1B,C in the supplementary material). There was no Cre activity in osteoclasts in bone marrow (data not shown). These results suggest that osteoclasts in cKO bone marrow are intact but cannot accomplish osteoclastogenesis, partly because of a defect in RANKL-OPG signaling in *Bmpr1a*-deficient osteoblasts. Taken together, these data suggest that the reduced osteoclastogenesis in cKO calvaria (Fig. 3) is primarily caused by defects in osteoblasts.


### Upregulation of canonical Wnt signaling in cKO bones

Both BMP and Wnt signaling (Baron et al., 2006; Glass and Karsenty, 2006; Hartmann, 2006; Krishnan et al., 2006) regulate bone mass. However, there is no described interaction between the

two in either mouse models or human mutation. We first investigated canonical Wnt signaling in cKO bones using *TOPGAL* Wnt reporter mice. The Wnt signaling assessed by  $\beta$ -gal staining was increased in cKO calvariae at E17.5 (Fig. 4A). Relative number of  $\beta$ -gal-positive cells was 8.5 times higher in cKO calvariae compared with wild type, which was significant (Fig. 4C). Although it is known that endogenous levels of canonical Wnt signaling assessed using *TOPGAL* mice are low in osteoblasts during embryonic bone development (Hens et al., 2005), the intensity of  $\beta$ -gal staining was dramatically increased in cKO long bones compared with wild type (Fig. 4D,E). These suggest that canonical Wnt signaling in cKO mice was stimulated during both endochondral and intramembranous ossification. Thus, *Bmpr1a* deficiency in osteoblasts upregulates Wnt signaling at least through the canonical pathway.

### Downregulation of sclerostin in cKO bones

Alteration of Wnt-related genes were further examined. Sclerostin (*Sost*) expression was consistently reduced by 95% in cKO calvariae from E16.5 to E18.5 when assessed with QRT-PCR (Fig. 5A) and was the most severely downregulated at E18.5 on microarray data ( $-5.68$ -fold,  $P=3.27E^{-24}$ ) (see Fig. S2 in the supplementary material). Expression levels of Wnt target genes




**Fig. 3. Alteration of bone formation and resorption in *Bmpr1a* cKO mice.** (A) QRT-PCR for bone formation markers (*Runx2*, *Sp7*, *Ibsp*, *Akp2* and *Bglap2*) using E16.5 and E18.5 calvariae. Values are expressed relative to wild type at E16.5. (B) QRT-PCR for bone resorption markers expressed by osteoclasts (*Mmp9*, *Ctsk* and *Trap*), and *Rankl* and *Opg* expressed by osteoblasts using E18.5 and E19.5 calvariae. Values are expressed relative to wild type at E18.5. (C) Relative ratio of *Rankl* to *Opg* expression levels calculated from Fig. 3B. Values are expressed relative to wild type at E18.5. (D) Evaluation of osteoclast activity by TRAP staining using E18.5 calvariae. The positive cells localized randomly in cKO calvariae compared with wild type (left two panels, red arrows). The percent of TRAP-positive cells per total cells in bone area detected by DAPI was significantly reduced in cKO calvariae (wild type, 13.9%; cKO, 6.4%, right panel). Scale bars: 50  $\mu$ m. (E) QRT-PCR for BMP type I receptors (*Bmpr1b*, *Acvr1*), type II receptors (*Bmpr2*, *Acvr2a* and *Acvr2b*) and potential ligands for these receptors (*Bmp2*, *Bmp4*, *Bmp6* and *Bmp7*) using E18.5 calvariae. Values in A-E represent mean $\pm$ s.d. from a minimum of three independent experiments using wild-type and cKO bones. Student's t-test; \* $P$ <0.05.

*Axin2* and *Ctgf* were significantly increased in cKO calvariae at E18.5 when assessed with QRT-PCR (Fig. 5B), but those of Wnt ligands (*Wnt3a*, *Wnt5a*, *Wnt7a*, *Wnt7b* and *Wnt9a*), other Wnt inhibitors [dickkopf 1 (*Dkk1*), *Dkk2* and secreted frizzled-related proteins] and co-receptor *Lrp5* were unchanged both when assessed with microarray and QRT-PCR at E18.5 (Fig. 5A, data not shown). Immunohistochemistry using E17.5 cKO calvariae confirmed that *Bmpr1a* deficiency in osteoblasts and osteocytes correlated with increased levels of  $\beta$ -gal staining and reduced production of sclerostin at cellular levels (Fig. 5C,D). The reduction of sclerostin was reproduced in vitro using primary osteoblasts from newborn cKO mice (Fig. 5E). Similarly, *Sost* expression was 90% reduced by loss of BMPR1A when assessed using adenoviral Cre infection in vitro (see Fig. S1A in the supplementary material). These results suggest that sclerostin is a downstream effector of BMPR1A on Wnt signaling, and that *Bmpr1a* deficiency in osteoblasts increased canonical Wnt signaling at least by the suppression of sclerostin.

### Wnt inhibitor sclerostin regulates bone mass

The effect of sclerostin on Wnt signaling and bone mass was further examined using *Bmpr1a*-deficient calvariae treated with 4-hydroxyl TM for 5 days ex vivo. Cre-dependent DNA recombination and upregulated Wnt signaling were confirmed by  $\beta$ -gal staining using *R26R* and cKO:*TOPGAL* newborn calvariae,

respectively (Fig. 6A, parts a,b). Expression levels of *Bmpr1a* and *Sost* were significantly reduced by 80% and by 90%, respectively, but *Dkk1*, *Dkk2* and *Lrp5* were unchanged (Fig. 6A, parts c,d). After treatment with 4-hydroxyl TM for 5 days, expression levels of bone resorption markers *Mmp9*, *Ctsk* and *Trap* were significantly reduced when assessed by QRT-PCR (Fig. 6A, part d), consistent with in vivo results (Fig. 4A, Fig. 5A). Next, when sclerostin was added in the culture, both canonical Wnt signaling and bone thickness were reduced in cKO calvariae (cKO+Scl, Fig. 6B), and the ratio of  $\beta$ -gal positive cells was significantly reduced (cKO, 65.3%; cKO+Scl, 17.2%). The expression levels of osteoclast markers *Rankl* and *Opg*, and the ratio of *Rankl* to *Opg* were partially restored in the cKO compared with wild type (Fig. 6C). Moreover, TRAP staining pattern in the cKO resembled that in the wild type in response to sclerostin treatment (Fig. 6D, compare with Fig. 3D). These results suggest that exogenous sclerostin in *Bmpr1a*-deficient calvariae partially restore morphological changes, Wnt signaling and osteoclastogenesis. In addition, Noggin treatment ex vivo reduced *Sost* expression by 85% and upregulated the Wnt signaling (see Fig. S3A,B in the supplementary material). Noggin antagonizes both BMP2 and BMP4, which are potent ligands of BMPR1A. Thus, we conclude that loss of BMP signaling reduces *Sost* expression, and sclerostin inhibits canonical Wnt signaling as a bone mass regulator during embryonic bone development.



**Fig. 4. Upregulation of canonical Wnt signaling in *Bmpr1a* cKO mice.** (A) Canonical Wnt signaling assessed by TOPGAL mice using E17.5 calvariae (upper panel, lateral view; lower panel, top view). Two independent parietal bones from two littermates in each group after dissection are shown in the right-hand panel. Red arrow indicates enhanced Wnt signaling. Broken line, areas of parietal bones (P). (B) Histological analysis assessed by TOPGAL mice using E17.5 calvariae. Scale bars: 50  $\mu$ m. (C) Relative cell number of DAPI and  $\beta$ -gal positive cells. Cells were counted in 50 fields of E17.5 calvariae from cKO ( $n=4$ ) and wild type ( $n=4$ ). Total cell number was obtained by counting DAPI-positive nuclei in bone. Cell number of wild type is set as 1.0. There were 2.3 times more total cells in cKO calvariae in a given section than in wild type owing to the thicker tissues, but the number of  $\beta$ -gal-positive cells was 19.7 times greater, resulting in an 8.5-fold increase in the proportion of  $\beta$ -gal positive cells in cKO mice. (D) Canonical Wnt signaling assessed by TOPGAL mice using humerus, ulna and radius at E17.5. Red arrow indicates enhanced Wnt signaling. (E) Histological analysis assessed by TOPGAL mice using radius at E17.5. Asterisks, growth plates. Scale bars: 100  $\mu$ m.

### Smad-dependent BMPR1A signaling upregulates sclerostin expression in vivo

To reveal the effects of Smad-dependent BMPR1A signaling on sclerostin expression and bone morphology in vivo, we generated inducible transgenic mice expressing *caBmpr1a* (constitutively activated *Bmpr1a*) in osteoblasts (see Fig. S4A in the supplementary material). After daily TM injection from E13.5 to E17.5, gross morphology of *caBmpr1a* fetuses was relatively normal at E18.5 (data not shown). Histology showed moderately reduced thickness in *caBmpr1a* calvariae (*Cre*<sup>+</sup>, *caBmpr1a*<sup>+</sup>) at E18.5, where levels of phosphorylated Smads were enhanced compared with controls (*Cre*<sup>-</sup>, *caBmpr1a*<sup>+</sup>) (Fig. 7A). *Sost* expression when assessed by QRT-PCR increased approximately sevenfold in the transgenic calvariae at E18.5, indicating that Smad signaling positively controls *Sost* expression. Expressions of bone resorption markers were all increased over fourfold, and *Rankl* levels increased four times while *Opg* levels decreased 40% (Fig. 7B), resulting in a 6.5-fold increase

in the ratio of *Rankl* to *Opg* (Fig. 7C). Expression of bone formation markers was also increased in the *caBmpr1a* (see Fig. S4B in the supplementary material). These changes observed in the *caBmpr1a* were the opposite of those seen in *Bmpr1a* cKO calvariae (Fig. 3). We next generated rescue mice expressing *caBmpr1a* on a *Bmpr1a* cKO background (*Cre*<sup>+</sup>, *caBmpr1a*<sup>+</sup>, *Bmpr1afx/fx*) and compared them with littermate *Bmpr1a* cKO mice (cKO: *Cre*<sup>+</sup>, *caBmpr1a*<sup>-</sup>, *Bmpr1afx/fx*). In E18.5 calvariae from rescued mice, expression of *Sost*, *Rankl* and osteoclast markers increased over four times (Fig. 7D), and the ratio of *Rankl* to *Opg* increased about 2.5-fold (Fig. 7E) when compared with the cKO. There was also a reduction in morphological changes observed in littermate *Bmpr1a* cKO mice (Fig. 7F). These results strongly suggest that *Sost* expression is regulated by BMPR1A signaling at least through the Smad pathway.

### DISCUSSION

This study showed that loss of BMPR1A increased bone mass and leads to two possibilities: (1) that BMPR1A signaling directly regulates osteoclastogenesis through RANKL-OPG pathway; or (2) indirectly regulates them via secondary mediator sclerostin as a Wnt inhibitor (Fig. 8). Both indicate that BMP signaling in osteoblasts restrains bone mass.

### BMP signaling, bone formation and bone mass

By using a 3.2 kb mouse pro-collagen  $\alpha 1(I)$  promoter (Rossert et al., 1995), we demonstrate that reduction in BMP signaling through BMPR1A in osteoblasts increased bone mass during embryonic stages. This is consistent with our previous report that showed increased bone volume (BV/TV) at 10 months by loss of BMP signaling in osteoblasts, using *Og2-Cre* mice in which osteoblasts initiate Cre expression postnatally. However, it is not consistent with 3-month-old mice, which showed decreased bone mass (Mishina et al., 2004). The bone phenotype observed in *Bmpr1a*-deficient mice with *Og2-Cre* was milder than that with *Col1-CreER*<sup>TM</sup>. These discrepancies may be due to differences in the timing of recombination between promoters. As characteristics of osteoblasts change as they mature (Aubin, 1998), the effects of disrupting BMPR1A signaling may be influenced by the stages of osteoblast maturation. In *Col1-CreER*<sup>TM</sup> mice, Cre activity was detected in immature periosteum that wraps growth plates, in osteogenic centers and in bone collars (Fig. 1B), indicating that Cre activation occurs just after commitment of mesenchymal cells towards osteoblastic cells. Therefore, *Col1-CreER*<sup>TM</sup> mice can induce recombination earlier in osteoblastogenesis, including in preosteoblasts, compared with *Og2-Cre* mice, which could explain why the *Bmpr1a*-deficient mice using *Og2-Cre* mice did not change expression levels of early osteogenic markers *Runx2* and *Bsp*, and showed mild bone phenotype (Mishina et al., 2004).

Expression levels of bone formation markers (*Runx2*, *Sp7*, *Ibsp*, *Akp2* and *Bglap2*) were increased more than twofold in *caBmpr1a* mice (see Fig. S4B in the supplementary material), indicating that BMP signaling through Smad1/5/8 induces osteoblastogenesis, as is well known in vitro (Chen et al., 2004). Some of these markers (*Runx2*, *Sp7* and *Ibsp*) were reduced in cKO bones as expected (Fig. 3A), consistent with the modest decrease in Smad phosphorylation levels (Fig. 1E) and our previous report that loss of BMP signaling decreases bone formation rate over bone surface (BFR/BS) during adulthood (Mishina et al., 2004). It is also suggested that normal bones respond to endogenous BMPs by phosphorylating Smads at a very low level, which is difficult to detect by immunostaining (Fig. 7A). It is possible that proliferation of osteoblasts is increased in cKO bones, which could influence increased bone mass; however,


this is less likely because the number of BrdU-positive cells per total cells in bone was unchanged (Fig. 2E). Histomorphometric analysis of bone is an established method to assess bone formation but is technically unfeasible in fetuses. Thus, we applied histomorphometry to adult cKO mice, where we confirmed osteoblasts failed to support osteoclastogenesis (see Fig. S1B in the supplementary material). Bone volume (BV/TV) was significantly increased, but formation rate (BFR/BS) and osteoclast number per bone area (N.Oc/T.Ar) were significantly decreased and osteoblast surface per bone surface (Ob.S/BS) were unchanged in the adult cKO (Kamiya et al., 2008). Similar to embryonic cKO data (Fig. 3), expression levels of osteoclast markers and the ratio of *Rankl* to *Opg* were significantly reduced when assessed by QRT-PCR in the adult cKO (Kamiya et al., 2008). These results suggest that osteoblast number is unchanged and bone formation is modestly reduced, while resorption markedly decreases in cKO bones, resulting in a net increase in bone mass. In addition, BMP signaling can control bone formation and resorption by inducing both osteoblastogenesis and osteoclastogenesis in vivo.

### RANKL-OPG pathway involved in BMP signaling


This study found that osteoblasts respond to BMP signaling to support differentiation of osteoclasts at least through the RANKL-OPG pathway. The link between BMP signaling and the RANKL-OPG pathway has been reported in vitro, showing that BMP2 enhances osteoclastogenesis by upregulating *Rankl* (Itoh et al., 2001; Usui et al., 2008). However, the link is not detected in those mice overexpressing *Noggin* or *Bmp4* in osteoblasts using a 2.3 kb type I collagen promoter (Okamoto et al., 2006) or by knocking out BMPR1A using an osteocalcin promoter (*Og2-Cre*) (Mishina et al., 2004), whereas osteoclastogenesis is upregulated by BMP signaling. As the 2.3 kb type I collagen and osteocalcin promoter are first activated in mature osteoblasts (Ducy and Karsenty, 1995; Kalajzic et al., 2002), immature osteoblasts, where the 3.2 kb type I collagen

promoter is active, may be crucial for regulating osteoclastogenesis through the RANKL-OPG pathway. Furthermore, it is possible that BMP signaling directly controls osteoclastogenesis through the RANKL-OPG signaling pathway probably by downregulating *Opg* expression in addition to upregulating *Rankl*, because BMP response elements were identified in the *Opg* promoter by Evolutionary Conserved Regions (ECR) browser search (data not shown). Further analysis is necessary to clarify the direct regulation of RANKL-OPG pathway by BMP signaling.

It is also possible that secondary mediators such as Wnts regulate expression of RANKL and OPG. Two recent studies have suggested that Wnt signaling in osteoblasts through the canonical  $\beta$ -catenin pathway not only boosts bone formation by fostering osteoblast activity but can also inhibit bone resorption by affecting osteoclasts (Goldring and Goldring, 2007). One study provided evidence that the Wnt pathway positively regulates osteoblast expression of osteoprotegerin (OPG) by overexpressing stabilized  $\beta$ -catenin in osteoblasts in mice, resulting in decreased osteoclast differentiation and increased bone volume (Glass et al., 2005). Another study showed that osteoblasts lacking the  $\beta$ -catenin gene exhibited impaired maturation and mineralization with elevated expression of *Rankl* and diminished *Opg*, suggesting that the Wnt pathway can suppress osteoclast-mediated bone resorption (Holmen et al., 2005). In our study, expression levels of *Opg* and *Rankl* as well as osteoclast markers (*Mmp9*, *Ctsk* and *Trap*) were partially restored by exogenous sclerostin ex vivo with a concomitant reduction in Wnt signaling (Fig. 6). Similarly, Wnt inhibitors Dkk1 and Dkk2 can induce osteoclastogenesis by changing the RANKL-OPG pathway in vitro (Fujita and Janz, 2007). These facts suggest that Wnt inhibitors in the canonical/ $\beta$ -catenin pathway enhance osteoclastogenesis. In addition, Wnt/ $\beta$ -catenin-responsive LEF1-binding sites were identified both in the *Opg* promoter and the *Rankl* promoter by an ECR browser search (data not shown). These facts strongly suggest that the changes in *Bmpr1a*-deficient bones are due



**Fig. 5. Inhibition of canonical Wnt signaling by sclerostin in *Bmpr1a* cKO mice.** (A) QRT-PCR analysis for *Sost*, *Dkk1*, *Dkk2* and *Lrp5* using calvariae at E16.5, E17.5 and E18.5. Values are expressed relative to wild type at E16.5. Student's *t*-test; \**P*<0.05. (B) QRT-PCR analysis for Wnt target gene *Axin2* and *Ctgf* using E18.5 calvariae. Expression levels of *Axin2* and *Ctgf* were significantly increased in cKO calvariae. Student's *t*-test; \**P*<0.05. (C) Immunohistochemical staining of sclerostin (brown) counterstained with Hematoxylin (blue) using E17.5 calvariae. Broken line, osteoblasts. Scale bars: 50  $\mu$ m, left panel; 10  $\mu$ m, right panel. (D) Detection of BMPR1A (green), canonical Wnt signaling (blue) and sclerostin (red) using E17.5 calvariae. Canonical Wnt signaling was assessed by  $\beta$ -gal staining using *TOPGAL* mice. Nuclei were stained with DAPI (blue). Broken line, osteoblasts. Scale bars: 20  $\mu$ m. (E) Immunohistochemical staining for sclerostin (red) in primary osteoblasts from *Bmpr1a* cKO and wild-type control. Nuclei were stained with DAPI (blue). Scale bars: 20  $\mu$ m.



**Fig. 6. Suppressed expression of sclerostin by loss of BMP signaling ex vivo.** (A) Newborn mouse calvariae were cultured for 5 days treated with 4OH-TM (100 ng/ml). (a) Confirmation of Cre activity in the calvariae from *CreER:R26R* mice assessed by  $\beta$ -gal staining. (b) Upregulation of canonical Wnt signaling in the calvariae from *CreER:Bmpr1afx/fx:TOPGAL* mice assessed by  $\beta$ -gal staining. Broken lines, areas of parietal bones (P). (c) Expression of Wnt inhibitors *Sost*, *Dkk1*, *Dkk2* and *Lrp5* assessed by QRT-PCR. (d) Expressions of bone resorption markers *Mmp9*, *Ctsk*, *TRAP* and *Bmpr1a*. Values are expressed relative to those of wild type (Cre-, TM-). (B) Sclerostin treatment of wild-type (WT+Scl) and cKO (cKO+Scl) calvariae ex vivo. The ratio of  $\beta$ -gal to DAPI-positive cells was evaluated from 50 fields in frontal sections ( $n=3$ , in each condition). Broken line, parietal bones. Scale bars: 50  $\mu$ m. (C) Expression of bone resorption markers *Rankl* and *Opg*, and relative ratio of *Rankl* to *Opg* using wild-type and cKO calvariae in sclerostin treated versus untreated groups. Values are expressed relative to those of wild type without sclerostin treatment. (D) TRAP staining of cKO calvariae treated with sclerostin and non-treated ex vivo. Values in A-C represent mean  $\pm$  s.d. from three independent experiments. Student's *t*-test; \* $P < 0.05$ .

to decreased bone resorption and osteoclastogenesis through the RANKL-OPG pathway, and that sclerostin is presumably involved in the pathway as a Wnt signaling inhibitor (Fig. 8).

### Sclerostin, a downstream target of BMPR1A


Sclerostin, which is encoded by *Sost*, has homology to the DAN family of BMP antagonists, which can control both BMP and Wnt signaling in *Xenopus* (Bell et al., 2003; Itasaki et al., 2003; Piccolo et al., 1999). However, although sclerostin directly binds BMPs (Kusu et al., 2003; Winkler et al., 2003), its antagonistic effects on BMP activity in mammals are still controversial. Recent in vitro studies showed that sclerostin is not a BMP antagonist (van Bezooijen et al., 2004), as it binds only weakly to BMPs and does not inhibit direct BMP-induced responses (ten Dijke et al., 2008). Together with the evidence from human mutations in *SOST* or its co-receptor *LRP5*, in vitro studies revealed that sclerostin is a Wnt inhibitor that binds LRP5 (Li et al., 2005; Semenov et al., 2005; van Bezooijen et al., 2007). Loss-of-function and hypomorphic mutations in *SOST* cause sclerosteosis (Balemans et al., 2001; Brunkow et al., 2001) and Van Buchem disease (Balemans et al., 2002; Staehling-Hampton et al., 2002), respectively, and bone mass is increased in these disorders, similar to *Sost* KO mouse (Li et al.,

2008). In human and mouse, these *Sost* mutants share the high bone mass (HBM) phenotype with humans who have gain-of-function mutations in *LRP5* (Boyden et al., 2002; Little et al., 2002; Van Wesenbeeck et al., 2003) and by overexpression of *Lrp5* in mice (Babij et al., 2003). By contrast, loss-of-function of *LRP5* leads to osteoporosis pseudoglioma syndrome in humans with low bone mass (Gong et al., 2001; Patel and Karsenty, 2002), which is similar to the bone phenotype of mice that overexpress *Sost* (Winkler et al., 2003). Consistent with these facts, *Bmpr1a* cKO mice show a HBM phenotype with lack of sclerostin expression. In addition, sclerostin differs from the BMP antagonist Noggin with respect to effects on Wnt signaling, as sclerostin inhibits Wnt (Fig. 6) whereas Noggin upregulates it (see Fig. S3A in the supplementary material). Thus, our study strongly suggests that sclerostin physiologically acts as an inhibitor of canonical Wnt signaling in vivo during embryonic bone development, and loss of sclerostin largely directs the *Bmpr1a* cKO bone phenotype.

The phenotype of *Sost* KO mice (Li et al., 2008) is different from that observed in *Bmpr1a* cKO with respect to the morphology of the bone, as *Bmpr1a* cKO mice showed disorganized bone structure (Fig. 2), which is not described in *Sost* KO mice (Li et al., 2008) or *SOST* human disorders. This fact implies that BMPR1A is not only




### Fig. 7. Enhanced BMPR1A signaling upregulates both sclerostin and osteoclastogenesis.



an upstream effector of sclerostin but also has other roles beyond regulating *Sost* in the osteoblasts. In the *Sost* KO there is no increase in osteoclast number or erosion surface, which is consistent with mice overexpressing *LRP5* with HBM phenotype (Babij et al., 2003), suggesting that bone formation and resorption are uncoupled in these mutants. However, as we discussed earlier, loss of BMP signaling reduced both bone formation and resorption together. In addition, the diameter of collagen fibrils in *Bmpr1a* cKO bones were

heterogeneous, aggregations of collagen fibers were disorganized and MMP expression levels were reduced (data not shown), suggesting that BMP signaling additionally regulates proper bone structure and turnover. In support of our speculation, reduction in osteoclastogenesis was not fully restored by sclerostin treatment *ex vivo* (Fig. 6C). These facts suggest that BMP signaling in osteoblasts directly regulates bone resorption independently of Wnt signaling through sclerostin, which in turn maintains proper bone structure and bone mass.

*Sost* expression was dramatically downregulated by removal of *Bmpr1a* *in vivo*, whereas it was upregulated by enhancing Smad-dependent BMPR1A signaling using *caBmpr1a*. It is reported that both BMP2 and BMP4, potent ligands of BMPR1A, induce *Sost* expression in mouse and human osteoblasts (Ohyama et al., 2004; Sutherland et al., 2004). Although sclerostin is produced primarily by osteocytes in adult bones (Poole et al., 2005; van Bezooijen et al., 2004), it is also detected in osteoblasts before birth (Fig. 5), suggesting the positive regulatory role of BMPR1A signaling in *Sost* expression both in osteoblasts and osteocytes during embryonic bone development. Interestingly, the promoter region of the *Sost* gene contains putative BMP response elements that were detected by an ECR browser search (data not shown), suggesting possible regulation of *Sost* by BMP signaling at the transcriptional level.



**Fig. 8. A model of the relationship between BMPR1A and canonical Wnt signaling in mouse bone.** BMPR1A signaling upregulates sclerostin expression, leading to an inhibition of canonical Wnt signaling and a decrease in bone mass by upregulating osteoclastogenesis through the RANKL-OPG pathway. Sclerostin, the *SOST* gene product, acts as a downstream effector of BMPR1A signaling, an inhibitor of canonical Wnt signaling and a bone mass-determining factor. Broken line indicates another possibility: that BMP signaling directly upregulates osteoclastogenesis through the RANKL-OPG pathway.

### Interaction of BMP and Wnt signaling in bone

Accumulating evidence suggests that both BMP and Wnt signaling may regulate each other in a context and age-dependent manner (Barrow et al., 2003; Guo et al., 2004; He et al., 2004; Huelsken et al., 2001). Only a few cascades such as Pten/Akt (Zhang et al., 2006) and Smad1/Dvl1 (Liu et al., 2006) are reported in intracellular crosstalk between the BMP and Wnt pathways. However, as in bone, the interaction between BMP and Wnt signaling is not well described generally *in vivo*, partly because alteration of BMP

signaling has not been studied in Wnt signaling mutants and vice versa. Some in vitro studies have demonstrated that both BMP and Wnt pathways synergistically regulate each other possibly through autocrine/paracrine loop, as BMPs induce Wnts in C2C12 cells and primary osteoblasts (Chen et al., 2007; Rawadi et al., 2003), and Wnt signaling, on the contrary, enhances BMPs expression in C3H10T1/2 cells (Bain et al., 2003; Winkler et al., 2005). These studies indicate that BMP signaling may upregulate Wnt signaling.

By contrast, our in vivo study suggests that BMP signaling downregulates Wnt signaling, as loss of BMPRI1A signaling upregulates Wnt signaling by inhibiting *Sost* expression. These discrepancies are partly due to the differences of cell type examined, as both osteoblasts and osteoclasts always affect each other as coupling factors in vivo, and coupling effects on the two signaling pathways are difficult to address using osteoblasts alone in vitro. Furthermore, it is also difficult for in vitro studies to address age-dependent changes in both signaling pathways and their interactions. Similar to our results, other studies have shown antagonistic interaction of BMP and Wnt signaling in lung (Dean et al., 2005), intestine (He et al., 2004), hair (Zhang et al., 2006) and joints (Guo et al., 2004). Moreover, Noggin treatment ex vivo upregulated canonical Wnt signaling and downregulated *Sost* expression (see Fig. S3A,B in the supplementary material), presumably by antagonizing BMP2 and BMP4, ligands for BMPRI1A. Thus, our study strongly suggests that BMPRI1A signaling in osteoblasts regulates negatively canonical Wnt signaling through downstream effector sclerostin during embryonic bone development.

In conclusion, we demonstrate a new interaction between the BMP and Wnt signaling pathways in osteoblasts through sclerostin, a Wnt inhibitor and a bone mass regulator. BMP signaling via BMPRI1A directs osteoblasts to reduce bone mass in part by upregulating sclerostin expression and supporting osteoclastogenesis through the RANKL-OPG pathway.

We gratefully thank Tomokazu Fukuda and Greg Scott for generation of *caBmpr1a* mouse line and Donald Lucas for critical reading of this manuscript. This work was supported by NIH grants P01 DK56246 (H.K.), R01 AR051587 (J.F.), R21 AR052824 (M.Y.), ES071003-11 and a conditional gift from RIKEN Brain Science Institute (Y.M.) and Lilly Fellowship Foundation (N.K.).

#### Supplementary material

Supplementary material for this article is available at <http://dev.biologists.org/cgi/content/full/135/22/3810/DC1>

#### References

- Aubin, J. E. (1998). Advances in the osteoblast lineage. *Biochem. Cell Biol.* **76**, 899-910.
- Babij, P., Zhao, W., Small, C., Kharode, Y., Yaworsky, P. J., Bouxsein, M. L., Reddy, P. S., Bodine, P. V., Robinson, J. A., Bhat, B. et al. (2003). High bone mass in mice expressing a mutant LRP5 gene. *J. Bone Miner. Res.* **18**, 960-974.
- Bain, G., Muller, T., Wang, X. and Papkoff, J. (2003). Activated beta-catenin induces osteoblast differentiation of C3H10T1/2 cells and participates in BMP2 mediated signal transduction. *Biochem. Biophys. Res. Commun.* **301**, 84-91.
- Balemans, W., Ebeling, M., Patel, N., Van Hul, E., Olson, P., Dioszegi, M., Lacza, C., Wuys, W., Van Den Ende, J., Willems, P. et al. (2001). Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). *Hum. Mol. Genet.* **10**, 537-543.
- Balemans, W., Patel, N., Ebeling, M., Van Hul, E., Wuys, W., Lacza, C., Dioszegi, M., Dikkers, F. G., Hilderling, P., Willems, P. J. et al. (2002). Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. *J. Med. Genet.* **39**, 91-97.
- Bandyopadhyay, A., Tsuji, K., Cox, K., Harfe, B. D., Rosen, V. and Tabin, C. J. (2006). Genetic analysis of the roles of BMP2, BMP4, and BMP7 in limb patterning and skeletogenesis. *PLoS Genet.* **2**, e216.
- Baron, R., Rawadi, G. and Roman-Roman, S. (2006). Wnt signaling: a key regulator of bone mass. *Curr. Top. Dev. Biol.* **76**, 103-127.
- Barrow, J. R., Thomas, K. R., Boussadia-Zahui, O., Moore, R., Kemler, R., Capecchi, M. R. and McMahon, A. P. (2003). Ectodermal Wnt3/beta-catenin signaling is required for the establishment and maintenance of the apical ectodermal ridge. *Genes Dev.* **17**, 394-409.
- Bell, E., Munoz-Sanjuan, I., Altmann, C. R., Vonica, A. and Brivanlou, A. H. (2003). Cell fate specification and competence by Coco, a maternal BMP, TGFbeta and Wnt inhibitor. *Development* **130**, 1381-1389.
- Boyd, L. M., Mao, J., Belsky, J., Mitzner, L., Farhi, A., Mitnick, M. A., Wu, D., Insogna, K. and Lifton, R. P. (2002). High bone density due to a mutation in LDL-receptor-related protein 5. *New Engl. J. Med.* **346**, 1513-1521.
- Brunkow, M. E., Gardner, J. C., Van Ness, J., Paepker, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y. et al. (2001). Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cysteine knot-containing protein. *Am. J. Hum. Genet.* **68**, 577-589.
- Chen, D., Zhao, M. and Mundy, G. R. (2004). Bone morphogenetic proteins. *Growth Factors* **22**, 233-241.
- Chen, Y., Whetstone, H. C., Youn, A., Nadesan, P., Chow, E. C., Lin, A. C. and Alman, B. A. (2007). Beta-catenin signaling pathway is crucial for bone morphogenetic protein 2 to induce new bone formation. *J. Biol. Chem.* **282**, 526-533.
- Danielian, P. S., Muccino, D., Rowitch, D. H., Michael, S. K. and McMahon, A. P. (1998). Modification of gene activity in mouse embryos in utero by a tamoxifen-inducible form of Cre recombinase. *Curr. Biol.* **8**, 1323-1326.
- DasGupta, R. and Fuchs, E. (1999). Multiple roles for activated LEF/TCF transcription complexes during hair follicle development and differentiation. *Development* **126**, 4557-4568.
- Dean, C. H., Miller, L. A., Smith, A. N., Dufort, D., Lang, R. A. and Niswander, L. A. (2005). Canonical Wnt signaling negatively regulates branching morphogenesis of the lung and lacrimal gland. *Dev. Biol.* **286**, 270-286.
- Ducy, P. and Karsenty, G. (1995). Two distinct osteoblast-specific cis-acting elements control expression of a mouse osteocalcin gene. *Mol. Cell. Biol.* **15**, 1858-1869.
- Fujita, K. and Janz, S. (2007). Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. *Mol. Cancer* **6**, 71.
- Fukuda, T., Scott, G., Komatsu, Y., Araya, R., Kawano, M., Ray, M. K., Yamada, M. and Mishina, Y. (2006). Generation of a mouse with conditionally activated signaling through the BMP receptor, ALK2. *Genesis* **44**, 159-167.
- Glass, D. A., 2nd and Karsenty, G. (2006). Molecular bases of the regulation of bone remodeling by the canonical Wnt signaling pathway. *Curr. Top. Dev. Biol.* **73**, 43-84.
- Glass, D. A., 2nd, Bialek, P., Ahn, J. D., Starbuck, M., Patel, M. S., Clevers, H., Taketo, M. M., Long, F., McMahon, A. P., Lang, R. A. et al. (2005). Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. *Dev. Cell* **8**, 751-764.
- Goldring, S. R. and Goldring, M. B. (2007). Eating bone or adding it: the Wnt pathway decides. *Nat. Med.* **13**, 133-134.
- Gong, Y., Slee, R. B., Fukai, N., Rawadi, G., Roman-Roman, S., Reginato, A. M., Wang, H., Cundy, T., Glorieux, F. H., Lev, D. et al. (2001). LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. *Cell* **107**, 513-523.
- Guo, X., Day, T. F., Jiang, X., Garrett-Beal, L., Topol, L. and Yang, Y. (2004). Wnt/beta-catenin signaling is sufficient and necessary for synovial joint formation. *Genes Dev.* **18**, 2404-2417.
- Hartmann, C. (2006). A Wnt canon orchestrating osteoblastogenesis. *Trends Cell. Biol.* **16**, 151-158.
- Hayashi, S. and McMahon, A. P. (2002). Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. *Dev. Biol.* **244**, 305-318.
- He, X. C., Zhang, J., Tong, W. G., Tawfik, O., Ross, J., Scoville, D. H., Tian, Q., Zeng, X., He, X., Wiedemann, L. M. et al. (2004). BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling. *Nat. Genet.* **36**, 1117-1121.
- Hens, J. R., Wilson, K. M., Dann, P., Chen, X., Horowitz, M. C. and Wysolmerski, J. J. (2005). TOPGAL mice show that the canonical Wnt signaling pathway is active during bone development and growth and is activated by mechanical loading in vitro. *J. Bone Miner. Res.* **20**, 1103-1113.
- Holmen, S. L., Zylstra, C. R., Mukherjee, A., Sigler, R. E., Faugere, M. C., Bouxsein, M. L., Deng, L., Clemens, T. L. and Williams, B. O. (2005). Essential role of beta-catenin in postnatal bone acquisition. *J. Biol. Chem.* **280**, 21162-21168.
- Huelsken, J., Vogel, R., Erdmann, B., Cotsarelis, G. and Birchmeier, W. (2001). beta-Catenin controls hair follicle morphogenesis and stem cell differentiation in the skin. *Cell* **105**, 533-545.
- Itasaki, N., Jones, C. M., Mercurio, S., Rowe, A., Domingos, P. M., Smith, J. C. and Krumlauf, R. (2003). Wise, a context-dependent activator and inhibitor of Wnt signalling. *Development* **130**, 4295-4305.
- Ito, K., Udagawa, N., Katagiri, T., Iemura, S., Ueno, N., Yasuda, H., Higashio, K., Quinn, J. M., Gillespie, M. T., Martin, T. J. et al. (2001). Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand. *Endocrinology* **142**, 3656-3662.

- Kalajzic, I., Kalajzic, Z., Kaliterna, M., Gronowicz, G., Clark, S. H., Lichtler, A. C. and Rowe, D. (2002). Use of type I collagen green fluorescent protein transgenes to identify subpopulations of cells at different stages of the osteoblast lineage. *J. Bone Miner. Res.* **17**, 15-25.
- Kamiya, N., Ye, L., Kobayashi, T., Lucas, D. J., Mochida, Y., Yamauchi, M., Kronenberg, H. M., Feng, J. Q. and Mishina, Y. (2008). Disruption of BMP signaling in osteoblasts through type IA receptor (BMPRIA) increases bone mass. *J. Bone Miner. Res.* (in press).
- Krishnan, V., Bryant, H. U. and Macdougald, O. A. (2006). Regulation of bone mass by Wnt signaling. *J. Clin. Invest.* **116**, 1202-1209.
- Kronenberg, H. M. (2003). Developmental regulation of the growth plate. *Nature* **423**, 332-336.
- Kusu, N., Laurikkala, J., Imanishi, M., Usui, H., Konishi, M., Miyake, A., Thesleff, I. and Itoh, N. (2003). Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. *J. Biol. Chem.* **278**, 24113-24117.
- Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S. E. and Wu, D. (2005). Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. *J. Biol. Chem.* **280**, 19883-19887.
- Li, X., Ominsky, M. S., Niu, Q. T., Sun, N., Daugherty, B., D'Agostin, D., Kurahara, C., Gao, Y., Cao, J., Gong, J. et al. (2008). Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. *J. Bone Miner. Res.* **23**, 860-869.
- Little, R. D., Carulli, J. P., Del Mastro, R. G., Dupuis, J., Osborne, M., Folz, C., Manning, S. P., Swain, P. M., Zhao, S. C., Eustace, B. et al. (2002). A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. *Am. J. Hum. Genet.* **70**, 11-19.
- Liu, Z., Tang, Y., Qiu, T., Cao, X. and Clemens, T. L. (2006). A dishevelled-1/Smad1 interaction couples WNT and bone morphogenetic protein signaling pathways in uncommitted bone marrow stromal cells. *J. Biol. Chem.* **281**, 17156-17163.
- Livak, K. J. and Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. *Methods* **25**, 402-408.
- Mackie, E. J., Ahmed, Y. A., Tatarczuch, L., Chen, K. S. and Mirams, M. (2008). Endochondral ossification: how cartilage is converted into bone in the developing skeleton. *Int. J. Biochem. Cell Biol.* **40**, 46-62.
- Maes, C., Kobayashi, T. and Kronenberg, H. M. (2007). A novel transgenic mouse model to study the osteoblast lineage in vivo. *Ann. N. Y. Acad. Sci.* **1116**, 149-164.
- Mishina, Y., Suzuki, A., Ueno, N. and Behringer, R. R. (1995). Bmpr encodes a type I bone morphogenetic protein receptor that is essential for gastrulation during mouse embryogenesis. *Genes Dev.* **9**, 3027-3037.
- Mishina, Y., Hanks, M. C., Miura, S., Tallquist, M. D. and Behringer, R. R. (2002). Generation of Bmpr/Alk3 conditional knockout mice. *Genesis* **32**, 69-72.
- Mishina, Y., Starbuck, M. W., Gentile, M. A., Fukuda, T., Kasparcova, V., Seedor, J. G., Hanks, M. C., Amling, M., Pinero, G. J., Harada, S. et al. (2004). Bone morphogenetic protein type IA receptor signaling regulates postnatal osteoblast function and bone remodeling. *J. Biol. Chem.* **279**, 27560-27566.
- Ohyama, Y., Nifuji, A., Maeda, Y., Amagasa, T. and Noda, M. (2004). Spatiotemporal association and bone morphogenetic protein regulation of sclerostin and osterix expression during embryonic osteogenesis. *Endocrinology* **145**, 4685-4692.
- Okamoto, M., Murai, J., Yoshikawa, H. and Tsumaki, N. (2006). Bone morphogenetic proteins in bone stimulate osteoclasts and osteoblasts during bone development. *J. Bone Miner. Res.* **21**, 1022-1033.
- Patel, M. S. and Karsenty, G. (2002). Regulation of bone formation and vision by LRP5. *New Engl. J. Med.* **346**, 1572-1574.
- Piccolo, S., Agius, E., Leyns, L., Bhattacharyya, S., Grunz, H., Bouwmeester, T. and De Robertis, E. M. (1999). The head inducer Cerberus is a multifunctional antagonist of Nodal, BMP and Wnt signals. *Nature* **397**, 707-710.
- Poole, K. E., van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Lowik, C. W. and Reeve, J. (2005). Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. *FASEB J.* **19**, 1842-1844.
- Rawadi, G., Vayssières, B., Dunn, F., Baron, R. and Roman-Roman, S. (2003). BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. *J. Bone Miner. Res.* **18**, 1842-1853.
- Rossert, J., Eberspaecher, H. and de Crombrughe, B. (1995). Separate cis-acting DNA elements of the mouse pro-alpha 1(I) collagen promoter direct expression of reporter genes to different type I collagen-producing cells in transgenic mice. *J. Cell Biol.* **129**, 1421-1432.
- Semenov, M., Tamai, K. and He, X. (2005). SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. *J. Biol. Chem.* **280**, 26770-26775.
- Shore, E. M., Xu, M., Feldman, G. J., Fenstermacher, D. A., Cho, T. J., Choi, I. H., Connor, J. M., Delai, P., Glaser, D. L., LeMerrer, M. et al. (2006). A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. *Nat. Genet.* **38**, 525-527.
- Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M. S., Luthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T. et al. (1997). Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. *Cell* **89**, 309-319.
- Soriano, P. (1999). Generalized lacZ expression with the ROSA26 Cre reporter strain. *Nat. Genet.* **21**, 70-71.
- Staebling-Hampton, K., Proll, S., Paepker, B. W., Zhao, L., Charmley, P., Brown, A., Gardner, J. C., Galas, D., Schatzman, R. C., Bighton, P. et al. (2002). A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. *Am. J. Med. Genet.* **110**, 144-152.
- Sutherland, M. K., Geoghegan, J. C., Yu, C., Winkler, D. G. and Latham, J. A. (2004). Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts. *Bone* **35**, 448-454.
- ten Dijke, P., Krause, C., de Gorter, D. J., Lowik, C. W. and van Bezooijen, R. L. (2008). Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. *J. Bone Joint Surg. Am.* **90** (Suppl. 1), 31-35.
- Thomas, J. T., Lin, K., Nandedkar, M., Camargo, M., Cervenka, J. and Luyten, F. P. (1996). A human chondrodysplasia due to a mutation in a TGF-beta superfamily member. *Nat. Genet.* **12**, 315-317.
- Tsuji, K., Bandyopadhyay, A., Harfe, B. D., Cox, K., Kakar, S., Gerstenfeld, L., Einhorn, T., Tabin, C. J. and Rosen, V. (2006). BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. *Nat. Genet.* **38**, 1424-1429.
- Urist, M. R. (1965). Bone: formation by autoinduction. *Science* **150**, 893-899.
- Usui, M., Xing, L., Drissi, H., Zuscik, M., O'Keefe, R., Chen, D. and Boyce, B. F. (2008). Murine and chicken chondrocytes regulate osteoclastogenesis by producing RANKL in response to BMP2. *J. Bone Miner. Res.* **23**, 314-325.
- van Bezooijen, R. L., Roelen, B. A., Visser, A., van der Wee-Pals, L., de Wilt, E., Karperien, M., Hamersma, H., Papapoulos, S. E., ten Dijke, P. and Lowik, C. W. (2004). Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. *J. Exp. Med.* **199**, 805-814.
- van Bezooijen, R. L., Svensson, J. P., Eefting, D., Visser, A., van der Horst, G., Karperien, M., Quax, P. H., Vrieling, H., Papapoulos, S. E., ten Dijke, P. et al. (2007). Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. *J. Bone Miner. Res.* **22**, 19-28.
- Van Wesenbeeck, L., Cleiren, E., Gram, J., Beals, R. K., Benichou, O., Scopelliti, D., Key, L., Renton, T., Bartels, C., Gong, Y. et al. (2003). Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. *Am. J. Hum. Genet.* **72**, 763-771.
- Winkler, D. G., Sutherland, M. K., Geoghegan, J. C., Yu, C., Hayes, T., Skonier, J. E., Shpektor, D., Jonas, M., Kovacevich, B. R., Staehling-Hampton, K. et al. (2003). Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. *EMBO J.* **22**, 6267-6276.
- Winkler, D. G., Sutherland, M. S., Ojala, E., Turcott, E., Geoghegan, J. C., Shpektor, D., Skonier, J. E., Yu, C. and Latham, J. A. (2005). Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins. *J. Biol. Chem.* **280**, 2498-2502.
- Winnier, G., Blessing, M., Labosky, P. A. and Hogan, B. L. (1995). Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse. *Genes Dev.* **9**, 2105-2116.
- Yoon, B. S., Ovchinnikov, D. A., Yoshii, I., Mishina, Y., Behringer, R. R. and Lyons, K. M. (2005). Bmpr1a and Bmpr1b have overlapping functions and are essential for chondrogenesis in vivo. *Proc. Natl. Acad. Sci. USA* **102**, 5062-5067.
- Zhang, H. and Bradley, A. (1996). Mice deficient for BMP2 are nonviable and have defects in amnion/chorion and cardiac development. *Development* **122**, 2977-2986.
- Zhang, J., He, X. C., Tong, W. G., Johnson, T., Wiedemann, L. M., Mishina, Y., Feng, J. Q. and Li, L. (2006). BMP signaling inhibits hair follicle anagen induction by restricting epithelial stem/progenitor cell activation and expansion. *Stem Cells* **24**, 2826-2839.